Skip to content

Effect of fiuid therapy on Transient Tachypnea of Newborn

Comparison of Restricted fluid volume with Standard Fluid volume In management of Transient Tachypnea Of Newborn

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120925010933N10
Enrollment
80
Registered
2018-02-01
Start date
2016-02-20
Completion date
Unknown
Last updated
2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transient tachypnoea of newborn. Transient tachypnea of newborn

Interventions

Intervention group: First interventional group(control group) : Newborn with gestational age 37 to 41weeks and receipt srandard fluid therapy.second interventional group(study group) : Newborn with g

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
148 Days to 287 Days

Inclusion criteria

Inclusion criteria: Inclusion criteria : Newborns with gestational age 37 to 41 with Transient Tachypnea of Newborn that are hospitalized in 3 first days of birth

Exclusion criteria

Exclusion criteria: ????? ??? ???? ?? ?????? : ???? ????? ???? ??? ????? ??????? ???? ???????? ??? ???? ????? ????? ??????? ????? ??? (??? ??? ????) ??????????? ????????????? ?????? ?????(?? ???? ?????)? ????? ??? ???? ????? ???????? ?????? ???????? ??????? ??? ????????????? ???? ????? ?????? ??????????????? ?????????? ??????? ???Na>150 ?Bun>20 K>5???? ? ???????????1?? ?? ?? ???? ??? ?? ????

Design outcomes

Primary

MeasureTime frame
Transient Tachypnea Of Newborn. Timepoint: daily. Method of measurement: observation and record of respirtory rate per minute.

Secondary

MeasureTime frame
O2 requirement. Timepoint: daily. Method of measurement: per liter. per minute.;Hospitalization. Timepoint: date of discharge. Method of measurement: day.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.eghbalian

Hamedan University of Medical Sciences

eghbalian@umsha.ac.ir+98 81 3264 0020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026